Such as mentioned above, in the validation cohort, we were able to replicate findings of established laboratories in confirmed cases of NMO AQP4+ (two of four) and definite AIE/PNS (four of seven, in particular when the Ag was intracellular), which helped to validate our 96-well hiPSC derived CBA. The gene discussed is AQP4; the disease is paraneoplastic neurologic syndrome.